Brokers Offer Predictions for TARS Q1 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Lifesci Capital issued their Q1 2025 earnings per share estimates for Tarsus Pharmaceuticals in a research report issued on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville expects that the company will post earnings per share of ($0.78) for the quarter. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals' Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.48) EPS and Q3 2025 earnings at ($0.31) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million.

A number of other equities analysts have also issued reports on the stock. Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Barclays lowered their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Guggenheim restated a "buy" rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. The Goldman Sachs Group lifted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research note on Friday, November 15th. Finally, HC Wainwright reissued a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $61.33.

Remove Ads

Tarsus Pharmaceuticals Stock Performance

TARS traded up $1.83 during trading hours on Friday, hitting $44.55. The company's stock had a trading volume of 394,769 shares, compared to its average volume of 642,828. Tarsus Pharmaceuticals has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The firm has a market capitalization of $1.71 billion, a PE ratio of -11.75 and a beta of 1.01. The company has a 50-day simple moving average of $50.74 and a 200 day simple moving average of $43.48. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Toronto Dominion Bank purchased a new position in Tarsus Pharmaceuticals during the 4th quarter valued at about $105,714,000. Jennison Associates LLC increased its stake in Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company's stock valued at $71,653,000 after buying an additional 698,712 shares during the period. Lord Abbett & CO. LLC raised its holdings in shares of Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock worth $70,873,000 after acquiring an additional 685,111 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 189.4% during the 4th quarter. Millennium Management LLC now owns 644,010 shares of the company's stock valued at $35,659,000 after buying an additional 421,495 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Tarsus Pharmaceuticals by 2,088.8% in the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock worth $14,477,000 after acquiring an additional 420,057 shares in the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.